Informe nº Osteba D12-04. - Euskadi.net

26. Faurbye A, Rasch P, Bender Peterson P,Brandenborg G, Pakkenberg H. Neurologicalsymptoms in the pharmacotherapy ofpsychoses. Acta Psychiatr Scand. 1964; 40:10-26.27. Ferre F. Guía para el diagnóstico y manejode la toxicidad neurológica causada porneurolépticos. Madrid: Grupo GEOPTE.2000.28. Friedman JH, Feinberg SS, Feldman RG. Aneuroleptic malignant-like syndrome dueto levodopa therapy withdrawal. JAMA.1985; 254: 2.792-2.795.29. Gardos G, Cole J, Salomón M, Schniebolk S.Clinical forms of severe tardive dyskinesia.Am J Psychiatry. 1987; 144: 895-902.30. Giles TO, Modlin RK. Death associated withventricular arrhythmias and thioridazinehydrochloride. JAMA. 1968; 205: 108-110.31. Gilles M, Wilke A, Kopf D y cols. Antagonismof the serotonin (5-HT)-2 receptor and insulinsensitivity: implications for atypical antipsychotics.Psychosom Med. 2005; 67:748-751.32. Goldstein LE, Sporn J, Brown S y cols. Newonsetdiabetes mellitus and diabetic ketoacidosisassociated with olanzapine treatment.Psychosomatics. 1999; 40: 438-443.33. Greiner AC, Berry K. Skin pigmentation andcorneal and lens opacities with prolongedchlorpromazine therapy. Can Med Assoc J.1964; 90: 663-664.34. Haddad PM, Anderson IM. Antipsychotic-relatedQTc prolongation, torsade de pointesand sudden death. Drugs. 2002; 62:1649-1671.35. Haddad PM, Wieck A. Antipsychotic-inducedhyperprolactinaemia: mechanisms, clinicalfeatures and management. Drugs.2004; 64: 2291-2314.36. Haro JM, Novick D, Suarez D, Roca M. Antipsychotictreatment discontinuation inpreviously untreated patients with schizophrenia:36-month results from theSOHO study. 2009.37. J Psychiatric Res. 43(3): 265-273.38. Harrigan EP, Miceli JJ, Anziano R, Watsky E,Middle M et al. A Randomized evaluation ofthe effects of six antipsychotic agents onQTc, in the absence and presence of metabolicinhibition. 2004.39. International Pharmaceutical Abstracts. JClin Psychopharmacol. 24(1): 62-69.40. Henderson D, Cagliero E, Gray C y cols. Clozapine,diabetes mellitus, weight gain, andlipid abnormalities: a five year naturalisticstudy. Am J Psychiatry. 2000; 157: 975-981.41. Henderson DC. Atypical antipsychotic-induceddiabetes mellitus: how strong is the evidence?CNS Drugs. 2000; 16: 77-89.42. Henderson DC. Weight gain with atypicalantipsychotics: evidence and insights. J ClinPsychiatry. 2007; 68 Suppl. 12: 18: 18-26.43. Hirsch S, Weinberger D. Schizophrenia 2thedition. (Ed Blackwell Science). 2003.44. Honigfeld G, Arellano F, Sethi J, Bianchini A,Schein J. Reducing clozapina-related morbidityand mortality: 5 years experiencewith the Clozaril National registry. J ClinPsychiatry. 1998; 59 Suppl. 3: 3-7.45. Jones A, Rak I, Raniwalla J y cols. Weight changesin patients treated with Seroquel (quetiapina).Paper presented at the annual meetingof the American College of Neuropsychopharmacology,Acapulco, Mexico. 1999.46. Jung DU, Conley RR, Kelly DL y cols. Prevalenceof bone mineral density loss in Koreanpatients with chronic schizophrenia: across-sectional study. J Clin Psychiatry.2006; 67: 1.391-1.396.47. Kahn RS, Fleischhacker WW, Boter H, DavidsonM, EUFEST Study Grp. et al. Effectivenessof antipsychotic drugs in first-episodeschizophrenia and schizophreniform disorder:an open randomised clinical trial. Lancet.2008; 371(9618): 1.085-1.097.esTRaTegIas77